About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

21.20 +8.42 (+65.88%)
Streaming Delayed Price Updated: 3:43 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Here are the top movers in Friday's session. ↗
Via Chartmill
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
DAWN Stock Alert: Halper Sadeh LLC is Investigating Whether Day One Biopharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) Reports Q4 Revenue Beat but Wider Loss, Shares Dip ↗
Via Chartmill
News headline image
Why Did DAWN Skyrocket Over 65% Pre-Market Today? ↗
Pharma firm Servier is set to acquire Day One Biopharmaceuticals’ shares for $21.50 each in cash, valuing the deal at $2.5 billion. 
Via Stocktwits
News headline image
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise ↗
On Stocktwits, retail sentiment around DAWN stock stayed within the ‘extremely bullish’ territory over the past 24 hours. 
Via Stocktwits
Topics Economy
News headline image
Day One Bio (DAWN) Q4 2025 Earnings Transcript ↗
Day One Bio (DAWN) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit ↗
This telecom provider delivers fiber, cloud, and security services to businesses and consumers across U.S. and international markets. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
Keep an eye on the top gainers and losers in Monday's session. ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
News headline image
Day One Completes Acquisition of Mersana Therapeutics
Acquisition expands Day One’s pipeline with clinical-stage antibody drug conjugate (ADC) emiltatug ledadotin (Emi-Le) targeting rare cancer adenoid cystic carcinoma (ACC) 
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Mersana Therapeutics Stock Explodes Over 200% To Notch Best Day Ever As $285M Buyout Trumps Analyst Downgrades: Retail Cheers ‘Very Good Bargain’ ↗
Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement. 
Via Stocktwits
News headline image
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout ↗
Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio. 
Via Benzinga
News headline image
Mersana Catapults 200% On Day One Bio's Surprise Buyout ↗
Shares of Mersana Therapeutics catapulted early Thursday after Day One Biopharmaceuticals agreed to buy it. 
Via Investor's Business Daily
News headline image
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal ↗
The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday. 
Via Stocktwits
News headline image
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Day One Reports Third Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.